Abstracts tagged "Autoimmunity"

Abstract Number: 366 • 2018 ACR/ARHP Annual Meeting
Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
Fatima Alduraibi¹, Monica Lawrence², Larry Borish² and Adam Carlson³, ¹Department of Medicine, University of Virginia Health System, charlottesville, VA, ²Department of Medicine, Division of Allergy and Immunology, University of Virginia Health System, Charlottesville, VA, ³Department of Medicine, Division of Rheumatology, University of Virginia Health System, Charlottesville, VA
Background/Purpose: Common variable immunodeficiency (CVID) is one of the most common symptomatic primary immunodeficiency syndrome with an incidence of ~1 in 25,000 people. CVID is…
Abstract Number: 842 • 2018 ACR/ARHP Annual Meeting
Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis
M Molendijk¹, A Otten-Mus², P Asmawidjaja³, Dominique Baeten⁴ and Erik Lubberts⁵, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, AMC, Amsterdam, Netherlands, ⁵Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Interleukin-17 Receptor D (IL-17RD) otherwise known as similar expression of fibroblast growth factor genes (SEF) is often described as an inhibitor of multiple signaling…
Abstract Number: 1029 • 2018 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes As Immune Effectors in the Pathogenesis of Synovial Lesion in Antibiotic-Refractory Lyme Arthritis
Klemen Strle¹, Robert Lochhead², Ruslan Sadreyev³, Allen C. Steere⁴ and John Aversa⁵, ¹Department of Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, BOSTON, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, BOSTON, MA, ³Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Orthopaedics and Rehabilitation, Yale Medical Group , Yale University School of Medicine, New Haven, CT
Background/Purpose: Antibiotic-refractory Lyme arthritis (LA) is characterized by marked proliferative synovitis that persists for months-to-years after oral and IV antibiotic therapy for Borrelia burgdorferi. Although…
Abstract Number: 1082 • 2018 ACR/ARHP Annual Meeting
Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity
Jennifer L. Barnas, Lin Gao, Mary O'Connell, Jennifer Albrecht, Nida Meednu, R. John Looney and Jennifer Anolik, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an interferon-stimulated gene (ISG) signature typically attributed to interferon (IFN)-α. However, ISGs can be induced by other…
Abstract Number: 1971 • 2018 ACR/ARHP Annual Meeting
PLCG2 Variants Influence CVID Susceptibility: Expanding the Spectrum of PLCG2-Associated Immune Dysregulation
Ann Marie Szymanski¹, Kathleen Baysac¹, Hannah Marcy¹, Elizabeth Baskin¹, Joshua Milner² and Michael Ombrello¹, ¹Translational Genetics and Genomics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD
Background/Purpose: Immune dysregulation refers to alterations in immune signaling leading to development of autoimmunity, infection and atopic disease. Common variable immunodeficiency (CVID), a prototypic disorder…
Abstract Number: 2085 • 2018 ACR/ARHP Annual Meeting
Response Gene to Complement-32 Promotes Kidney Damage in Immune Complex –Mediated Glomerulonephritis
Anamaria Talpos-Caia^1,2, Vinh Nguyen^2,3, Alexandru Tatomir^3,4, Sun-sang Sung⁵, John Papadimitriou⁶, Sergei Atamas^2,3, Irina G. Luzina^2,3, Simona Rednic¹, Horea Rus^3,4 and Violeta Rus^2,3, ¹Rheumatology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania, ²Medicine, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ³Research Service, Veteran Affairs Medical Center, Baltimore, MD, ⁴Neurology, University of Maryland School of Medicine, Baltimore, MD, ⁵Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia School of Medicine, Charlottesville, VA, ⁶Pathology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Response Gene to Complement (RGC)-32 is a cell cycle regulator widely expressed in normal tissues including brain, kidney, spleen, thymus, multiple tumors and in…
Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Iago Pinal-Fernandez¹, Berta Ferrer-Fabregas², Ernesto Trallero-Araguas¹, Eva Balada¹, Maria Angeles Martinez³, Jose Cesar Milisenda⁴, Gloria Aparicio-Español⁵, Moises Labrador-Horrillo¹, Vicente Garcia-Patos¹, Josep Maria Grau-Junyent⁴ and Albert Selva O'Callaghan⁶, ¹Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, ²Pathology, Vall d´Hebron, Barcelona, Spain, ³Immunology, Immunology Department, Barcelona, Spain, ⁴Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, ⁵Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, ⁶Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…
Abstract Number: 1408 • 2017 ACR/ARHP Annual Meeting
The Cation Channel TRPV2 Decreases Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness By Inhibiting RhoA Activation, Cell Adhesion and Actin Cytoskeleton Changes
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have recently identified the non-selective cation channel TRPV2 (transient receptor potential vanilloid subfamily, type 2 channel) as a new central mediator of arthritis…
Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting
Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Danielle Baldo¹, Alessandra Dellavance¹, Maria Lucia Ferraz² and Luis Eduardo C. Andrade^3,4, ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Gastroenterology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…
Abstract Number: 2580 • 2017 ACR/ARHP Annual Meeting
Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block
Robert M. Clancy¹, Glenn Fishman¹, Colin Phoon¹, Marc Halushka², Tanisha Jackson¹, Kimberly Robins¹ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The most serious manifestation of fetal exposure to maternal anti-Ro antibodies is the development of heart block. This work addresses the hypothesis that fetal…
Abstract Number: 2583 • 2017 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Priya Prakash¹, Mark Tratenberg², Slavica Bobic³, Rui Zhang⁴, Kirk Sperber⁵, Amy Wasserman⁶ and Julia Ash⁷, ¹Medicine-Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY, ²New York Medical College / Westchester Medical Center, valhalla, NY, ³Medicine-Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁴Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁵New York Medical College / Westchester Medical Center, Valhalla, NY, ⁶Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ⁷Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY
Background/Purpose: MMF suppresses immune function by inhibiting T cell dependent and independent humoral immune responses. This study investigates the humoral immune response to the PPSV23…
Abstract Number: 2838 • 2017 ACR/ARHP Annual Meeting
Apoptotic Bodies Containing dsDNA Covalently Modified By Parvovirus B19 Non-Structural Protein NS1 Induce dsDNA Autoantibodies and End Organ Damage in Non-Autoimmune Mice
Stanley J. Naides¹, Kanoktip Puttaraksa², Heidi Pirttinen² and Leona Gilbert², ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Department of Biological and Environmental Science and Nanoscience Center, University of Jyvaskyla, Jyvaskyla, Finland
Background/Purpose: Persistent viral infections can induce aberrant immune responses and are implicated in the development of autoimmunity. Parvovirus B19 (B19V) non-structural protein, NS1, a helicase,…
Abstract Number: 831 • 2017 ACR/ARHP Annual Meeting
Interferon-Alpha Disrupts Tolerance in a Mouse Model of B Cell Anergy
Dario Ferri¹, Yuriy Baglaenko², Kieran Manion², Nan-Hua Chang² and Joan E. Wither³, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the production of anti-nuclear antibodies that deposit within tissues leading to organ damage. A central mediator of…
Abstract Number: 573 • 2016 ACR/ARHP Annual Meeting
Synovial Fibroblast-Neutrophil Interactions Promote Pathogenic Adaptive Immunity in Rheumatoid Arthritis
Carmelo Carmona-Rivera¹, Erica Moore², Nithya Lingampalli³, Hannes Uchtenhagen⁴, Eddie James⁵, Kevin L. Bicker⁶, Heidi Wähämaa⁷, Victoria Hoffmann⁸, Anca I Catrina⁷, Paul Thompson⁹, Jane H. Buckner⁵, William Robinson¹⁰, David Fox¹¹ and Mariana Kaplan², ¹Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Middle Tennessee State University, Murfreesboro, TN, ⁷Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁸Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, ⁹University of Massachusetts, Worcester, MA, ¹⁰Stanford University School of Medicine, Stanford, CA, ¹¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 576 • 2016 ACR/ARHP Annual Meeting
Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis
Scott Matson¹, Joshua J. Solomon², Jeffrey J. Swigris², Jonathan Chung³, Michael Mahler⁴, Kevin D. Deane⁵ and M. Kristen Demoruelle⁵, ¹Medicine, University of Colorado Denver, Aurora, CO, ²Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ³Radiology, University of Chicago Medical Center, Chicago, IL, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Rheumatology Division, University of Colorado Denver, Aurora, CO
Background/Purpose: In RA-associated interstitial lung disease (RA-ILD), higher levels of anti-CCP antibodies have been associated with the presence and severity of ILD suggesting a potential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].